These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32732675)

  • 1. Cancer Drugs in Asian Populations: Availability, Accessibility, and Affordability.
    Goh BC; Lim JF
    Cancer J; 2020; 26(4):323-329. PubMed ID: 32732675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating essential medicines for treating childhood cancers: availability, price and affordability study in Ghana.
    Mensah KB; Mensah ABB; Bangalee V; Padayachee N; Oosthuizen F
    BMC Cancer; 2021 Jun; 21(1):683. PubMed ID: 34112117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region.
    Salmasi S; Lee KS; Ming LC; Neoh CF; Elrggal ME; Babar ZD; Khan TM; Hadi MA
    BMC Cancer; 2017 Dec; 17(1):903. PubMed ID: 29282008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.
    Cherny NI; Sullivan R; Torode J; Saar M; Eniu A
    Ann Oncol; 2017 Nov; 28(11):2633-2647. PubMed ID: 28950323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Country and regional variations in purchase prices for essential cancer medications.
    Cuomo RE; Seidman RL; Mackey TK
    BMC Cancer; 2017 Aug; 17(1):566. PubMed ID: 28836947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China.
    Zhu Y; Wang Y; Sun X; Li X
    Int J Environ Res Public Health; 2019 Oct; 16(19):. PubMed ID: 31623326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.
    Parmar A; Jiao T; Saluja R; Chan KKW
    Cancer Med; 2020 Jan; 9(1):94-103. PubMed ID: 31711274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
    Dusetzina SB; Keating NL
    J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Problem of Cancer Drugs Costs: A Payer Perspective.
    Newcomer LN
    Cancer J; 2020; 26(4):287-291. PubMed ID: 32732670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cancer Journal Article for Theme Issue: The Problem of Cancer Drug Costs.
    Collyar DE
    Cancer J; 2020; 26(4):292-297. PubMed ID: 32732671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Universal Health Coverage and Cancer Drugs - A Cost-Effectiveness Perspective].
    Fukuda A; Igarashi A
    Gan To Kagaku Ryoho; 2016 Nov; 43(11):1311-1315. PubMed ID: 27899770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments.
    Aguiar PN; Adashek JJ; Roitberg F; Noia Barreto CM; Del Giglio A; Lopes GL
    Value Health Reg Issues; 2019 Dec; 20():47-50. PubMed ID: 30856543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?
    Zafar SY; Peppercorn JM
    J Clin Oncol; 2017 Jul; 35(19):2113-2116. PubMed ID: 28459612
    [No Abstract]   [Full Text] [Related]  

  • 14. Pricing and Paying for Cancer Drugs: Policy Options for Fixing A Broken System.
    Hyman DA; Silver C
    Cancer J; 2020; 26(4):298-303. PubMed ID: 32732672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches to improving access to essential cancer medicines in the WHO South-East Asia Region.
    Chivukula MV; Tisocki K
    WHO South East Asia J Public Health; 2018 Sep; 7(2):62-66. PubMed ID: 30136662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.
    Drummond M; de Pouvourville G; Jones E; Haig J; Saba G; Cawston H
    Pharmacoeconomics; 2014 May; 32(5):509-20. PubMed ID: 24599784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
    Shah-Manek B; Wong W; Ravelo A; DiBonaventura M
    J Manag Care Spec Pharm; 2018 Jun; 24(6):565-571. PubMed ID: 29451078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling the cost of innovative cancer therapeutics.
    Malik NN
    Nat Rev Clin Oncol; 2009 Sep; 6(9):550-2. PubMed ID: 19707244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.